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Background: Pure mucinous adenocarcinoma of the breast is a rare entity characterized by the production of
variable amounts of mucin comprising 1% to 6% of breast carcinomas. Some mucinous adenocarcinomas have
shown expression of intestinal differentiation markers such as MUC-2. This study examines the expression of
intestinal differentiation markers in this type of breast carcinoma.
Results: Twenty-two cases of pure mucinous adenocarcinoma of the breast were assessed. Immunochemistry was
performed for beta-catenin, CDX-2 and MUC-2. All cases were positive for B-catenin. MUC-2 positivity was observed
in all cases; 63. 6% were 3 plus positive. All cases were negative for CDX-2.
Conclusions: These results suggest that mucinous breast carcinomas express some markers of intestinal
differentiation, such as MUC-2 and beta-catenin; however, future studies with a larger series of cases and using
molecular techniques that help affirm these results are needed.
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Pure mucinous adenocarcinoma of the breast (PMACB)
is a rare entity characterized by the production of vari-
able amounts of mucin. It comprises approximately 1%
to 6% of breast carcinomas [1,2]. Pure mucinous carcin-
omas are those with a mucinous component of more
than 90% [3]. These tumors have a better prognosis than
mixed or non-mucinous tumors [4,5]. Mucin synthesis is
a common feature of glandular tissue and has been stud-
ied in various adenocarcinomas. Multiple studies of
PMACB have shown expression of the proteins MUC1,
MUC2, MUC3, MUC4, MUC5A and MUC6, and these
have been postulated as prognostic factors [6,7]. The
marker MUC2 is an intestinal-type mucin, which is
mainly expressed in normal goblet cells of the colon and
small intestine [8]. However, it is not only positive in
colon cancer [9]. Its expression has also been shown in
other mucinous carcinomas, which, despite their site of* Correspondence: bpositivo66@hotmail.com
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article, unless otherwise stated.origin (salivary glands, pancreas, bladder, stomach, cer-
vix, ovary, endometrium, and lung), share certain histo-
logical features. They are composed of glands lined with
either columnar mucin producing cells with abundant
extracellular mucin accumulation, or mucin-containing
signet ring cells [10-12]. There are few published studies
evaluating the expression of intestinal differentiation
markers such as MUC2 in PMACB. Most compare their
expression with usual ductal adenocarcinomas [6,7,13],
and there are none that exclusively analyze more specific
markers of intestinal differentiation, such as CDX-2 [14]
and beta-catenin [15] in pure mucinous adenocarcin-
omas of the breast.
Results
During the period of 12 years there were 36 cases, of which
only 22 (61.1%) were considered pure mucinous in their
reassessment. Thirteen cases (59%) were associated with
intraductal in situ carcinoma (DCIS). Mean age was
61 years (range 35–85) and mean tumor size was 2.49 cm
(range 0.9-4.5 cm).
All cases were positive for beta-catenin. The most
frequently observed pattern (36.4%) was proportion 4 and
strong intensity (>75% of cells). MUC2 positivity wasd Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Figure 1 Mucinous type adenocarcinoma of the breast, cases without DCIS. A. A representative histopathological image H&E 5x.
Immunohistochemical stains. B. MUC2 stain. C. Beta-catenin stain. D. CDX2 stain 10x.
Figure 2 Mucinous type adenocarcinoma of the breast, cases associated with DCIS. A. A representative histopathological image H&E 5x.
Immunohistochemical stains. B. MUC-2 stain. C. Beta-catenin stain. We interpreted the results as proportion 1 (10-25%) and weak intensity.
D. CDX2 stain 10x.
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were negative for CDX-2 (Figures 1 and 2).
We compared the expression of the previously men-
tioned markers between those cases associated with in situ
carcinoma and those without carcinoma in situ. This was
done to evaluate the relationship between this histological
parameter and the expression of intestinal differentiation
markers. However, we found no statistically significant
difference in any of the three markers (Table 1).Discussion
Since pure mucinous adenocarcinoma of the breast
(PMACB) is a variety of ductal carcinoma with specific
histological features, it has attracted the interest of several
authors for decades. Fujji et al. [16] demonstrated that
PMACB possess a smaller number of genetic alterations in
comparison with other variants of breast cancer. Lacroix-
Triki et al. [17] found less genetic instability, suggesting
that it is not only a histological entity, but also molecularly
distinct from common ductal adenocarcinoma. Others
studies, especially those from the late nineties, present the
neuroendocrine differentiation of these neoplasms, which
can occur in a variable percentage from 21% to 42% with
histochemical studies, immunohistochemistry, and ultra-
strcture [18-20]. The importance of this variety of breast
adenocarcinoma is that numerous studies have shown that
PMACB has a better prognosis than mixed or common
ductal types [4,5]. Volkan Adsay et al. [13] propose that
secretion of distinct mucin, specifically to the stromal
surface, acts as a container for neoplastic cells, reducing
their ability to disseminate. The findings of this study may
also explain why PMACB has a better prognosis than
common ductal carcinomas.
Another study demonstrated that PMACB secretes an
acetylated sialomucin, which is also found in mucinous
carcinomas of the colon and stomach [21]. Further-
more, immunohistochemical studies show that in
PMACB, the predominant molecule is MUC2 [6,7,13],
which is negative in normal breast tissue. MUC2 and
also, other intestinal secretory mucins [8,9], have been
found in other mucinous adenocarcinomas, such as
those of the pancreas [22], salivary glands [23], biliary
tract, the ampulla of Vater [24], the stomach [25], endo-
metrium [26], lung [27], and ovary [28], among others.Table 1 Comparison of expression of intestinal differentiation
Marker Without DCIS (n
Intestinal differentiation markers, n (%)
Beta-catenin 13 (100)
MUC 2 13 (100)
CDX-2 0
*No statistical value since all cases were negative.Expression of MUC proteins in breast adenocarcinoma
has been proposed as a prognostic factor. Specifically, the
MUC2 marker in common ductal adenocarcinoma has
been associated with less aggressive behavior, showing an
inverse relationship with the presence of vascular invasion
and lymph node metastasis [6,7].
Regarding beta-catenin, this is a cell adhesion molecule
that plays an important role in the Wnt signaling pathway.
When the Wnt beta-catenin pathway is activated, it is
translocated from the cell membrane to the cytoplasm
and the nucleus where it interacts with genes that activate
transcription factors [29]. Many studies have demon-
strated activation of this pathway in adenocarcinoma of
the breast [30,31]. Also, it plays an important role in colo-
rectal carcinogenesis, activating the APC gene pathway or
the Wnt signaling pathway [10]. In cases of colorectal
carcinoma, 90% show nuclear positivity for beta-catenin
[32]. Although both adenocarcinomas share this molecu-
lar pathway, we could not find any case of pure mucinous
adenocarcinoma of the breast that displays a nuclear
staining pattern similar to that of colon adenocarcinoma.
This agrees with the work by Peiguo Chu et al., who tried
to determine the site of origin of 175 cases of mucinous
adenocarcinoma. The authors included 18 cases that were
found to be primary breast tumors and none showed
nuclear positivity for beta-catenin [10]. Regardless of this,
the majority of studies of beta-catenin expression in
adenocarcinoma of the breast have tried to correlate its
expression with clinical behavior. Decreased expression or
aberrant expression has been associated with increased
frequency of positive lymph node metastasis, and overex-
pression of the HER2 neu and basal phenotype [30,31].
On the other hand, CDX2 is a gene belonging to the
homeobox gene family, which is required for intestinal
organogenesis and encoding nuclear transcription fac-
tors involved in the proliferation and differentiation of
intestinal epithelium. The highest frequency of CDX2
staining occurred in colorectal carcinomas when com-
pared with tumors from other sites. Therefore, the high
frequency of CDX2 staining in colorectal adenocarcin-
omas, staining in extraintestinal tumors with intestinal-
type epithelium, and uncommon staining in tumors
from various sites lacking an intestinal phenotype
sugg4ests that it is a useful marker for intestinal-type
differentiation [14,33]. O’Connell et al. [34] conducted aand the association with in situ carcinoma (DCIS)




Table 2 Intestinal differentiation markers and parameters used to evaluate positivity
Marker Mark Dilution Positivity Proportion Intensity




CDX 2 Biocare Medical CDX2-88 1: 50 Nuclear 25% = 1+ 1 + = weak
26-75% = 2+ 2 + = strong
>75% = 3+
B-catenin Santa Cruz E-5 1: 50 Membranous 0 = 0 – 10% 0 = Negative
1 = 10 – 25% 1 = weak
2 = 25 – 50% 2 =moderate
3 = 50 – 75% 3 = strong
4 = >75%
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guishing primary adenocarcinomas of the gastrointes-
tinal tract versus metastatic breast cancers, in which 47
adenocarcinomas involving the gastrointestinal tract
were examined, including 19 cases of primary breast
cancer. In their results, 100% of the cases from breast
were negative for CDX-2. The results of our work and
that of O’Connell are consistent with other studies in
which, despite constant expression of MUC 2 in
PMACB, no case showed positivity for CDX-2 [10].
However, among colorectal adenocarcinomas, the rela-
tionship between tumor grade and CDX2 staining has
been controversial. CDX2 does not appear to be a sensi-
tive marker for poorly differentiated colorectal carcin-
omas, and it is not a completely specific marker. Finally,
CDX2 also stains other non-intestinal mucinous tumors,
most notably carcinomas of lung, ovary and endomet-
rium [14]. This can be a ‘pitfall’ in assessing primary site
or of a metastatic mucinous tumor of unknown origin,
especially if it is poorly differentiated.
Although expression of these markers in other studies
has been associated with prognosis and other histo-
logical parameters, we found no statistically significant
differences between those cases with and without DCIS.
Conclusions
In conclusion the results of this study suggest that
mucinous breast carcinomas express some markers of
intestinal differentiation; however, future studies con-
taining a larger series and other molecular techniques
that help affirm the results of this study are required.
Methods
We performed a retrospective observational review of
pathological reports of patients with mucinous type
adenocarcinomas of the breast obtained from the
Pathology and Cytopathology Department of the UANLUniversity Hospital in Monterrey, Mexico in a period of
12 years (January 2000 to December 2011). We included
only cases with at least 90% mucinous differentiation. We
excluded those cases that did not have a paraffin block.
All cases were reevaluated with the usual technique of
hematoxylin and eosin, in 3 micron slices. The most
representative slice of each tumor was selected and
immunohistochemical staining was performed for beta-
catenin, CDX-2 and MUC2. The immunohistochemical
technique applied was based on the manufacturer’s
recommendations for each antibody. The antibodies,
company, dilutions and criteria used to evaluate positivity
are summarized in Table 2. These were based on previous
studies with the markers [6,10,29]. We included positive
and negative controls for each marker on each slide. For
statistical analysis, we used SPSS version 17.
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